Abstracts tagged "patient questionnaires and spondylarthropathy"

Abstract Number: 1425 • 2016 ACR/ARHP Annual Meeting
Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)
Clare Longton¹, Marco Massarotti² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Improving patient experience is important in all diseases, but most important in patients with chronic rheumatic diseases like the axial spondyloarthropathies (AxSpa). The Commissioning…
Abstract Number: 2880 • 2015 ACR/ARHP Annual Meeting
Real-World Impact of Anti-TNF Medication Use on Patient Reported Outcomes in a Prospective Cohort of Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Annelies Boonen², Helena Marzo-Ortega³, Marina N. Magrey⁴, Manish Mittal⁵, Michael Halpern⁶, Jeanette Renaud⁶, Yanjun Bao⁵ and Avani D. Joshi⁵, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Maastricht University Medical Center, Maastricht, Netherlands, ³LMBRU, Chapel Allerton Hospital, and University of Leeds, Leeds, United Kingdom, ⁴Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁵AbbVie Inc., North Chicago, IL, ⁶RTI International, Washington, DC
Background/Purpose: Clinical trial results have demonstrated benefits of anti-TNF therapy in improving clinical outcomes, including overall health-related quality of life (HRQoL) in patients with ankylosing…
Abstract Number: 586 • 2014 ACR/ARHP Annual Meeting
Helplessness in Coping Is Associated with Worse Patient Reported Outcomes Among Patients with Ankylosing Spondylitis: A Longitudinal Multi-Country Cohort Study
Walter P. Maksymowych¹, Annelies Boonen², Helena Marzo-Ortega³, Marina N. Magrey⁴, Manish Mittal⁵, Michael Halpern⁶, Jeannette Renaud⁶, Yanjun Bao⁵ and Avani D. Joshi⁵, ¹University of Alberta, Edmonton, AB, Canada, ²Maastricht University Medical Center, Maastricht, Netherlands, ³LMBRU, Chapel Allerton Hospital, and University of Leeds, Leeds, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ⁵AbbVie Inc., North Chicago, IL, ⁶RTI International, Washington, DC
Background/Purpose: Ankylosing spondylitis (AS) causes pain, joint damage and reduced function, which contribute to a substantial burden on affected patients and their families. A feeling…
Abstract Number: 552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis
Désirée van der Heijde¹, Manish Mittal², Naijun Chen², Aileen L. Pangan² and Avani D. Joshi², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL
Background/Purpose: In the ABILITY-1 trial, adalimumab (ADA) treatment for 12 weeks was associated with improved clinical and health-related quality of life (HRQOL) outcomes among patients…
Abstract Number: 1345 • 2012 ACR/ARHP Annual Meeting
Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis
Dennis Revicki¹, Wen-Hung Chen¹, Ying Jin¹, Sumati Rao², Philip J. Mease³ and Mary Cifaldi², ¹United Biosource Corporation, Bethesda, MD, ²Abbott Laboratories, Abbott Park, IL, ³Swedish Rheumatology Research Group, Seattle, WA
Background/Purpose: To evaluate the psychometric properties of the Health Assessment Questionnaire for Spondyloarthritis (HAQ-S) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods: Data from 185…
Abstract Number: 1353 • 2012 ACR/ARHP Annual Meeting
Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-52 Results From Ability-1
Désirée van der Heijde¹, Philip J. Mease², Aileen L. Pangan³, Sumati Rao⁴, Naijun Chen⁴ and Mary A. Cifaldi⁴, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Swedish Rheumatology Research Group, Seattle, WA, ³Abbott, Abbott Park, IL, ⁴Abbott Laboratories, Abbott Park, IL
Background/Purpose: To evaluate long-term effects of adalimumab (ADA) treatment on patient reported outcomes (PROs) in nonradiographic axial spondyloarthritis (nr-axSpA). Methods: Ability-1 is an ongoing Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].